JP2022525428A5 - - Google Patents

Info

Publication number
JP2022525428A5
JP2022525428A5 JP2021557397A JP2021557397A JP2022525428A5 JP 2022525428 A5 JP2022525428 A5 JP 2022525428A5 JP 2021557397 A JP2021557397 A JP 2021557397A JP 2021557397 A JP2021557397 A JP 2021557397A JP 2022525428 A5 JP2022525428 A5 JP 2022525428A5
Authority
JP
Japan
Application number
JP2021557397A
Other languages
Japanese (ja)
Other versions
JPWO2020198697A5 (https=
JP2022525428A (ja
JP7631215B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025513 external-priority patent/WO2020198697A1/en
Publication of JP2022525428A publication Critical patent/JP2022525428A/ja
Publication of JPWO2020198697A5 publication Critical patent/JPWO2020198697A5/ja
Publication of JP2022525428A5 publication Critical patent/JP2022525428A5/ja
Priority to JP2025016673A priority Critical patent/JP2025072483A/ja
Application granted granted Critical
Publication of JP7631215B2 publication Critical patent/JP7631215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021557397A 2019-03-28 2020-03-27 Ttrガイドrnaと、rnaガイドdna結合剤をコードするポリヌクレオチドとを含む組成物および方法 Active JP7631215B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025016673A JP2025072483A (ja) 2019-03-28 2025-02-04 Ttrガイドrnaと、rnaガイドdna結合剤をコードするポリヌクレオチドとを含む組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825637P 2019-03-28 2019-03-28
US62/825,637 2019-03-28
PCT/US2020/025513 WO2020198697A1 (en) 2019-03-28 2020-03-27 Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025016673A Division JP2025072483A (ja) 2019-03-28 2025-02-04 Ttrガイドrnaと、rnaガイドdna結合剤をコードするポリヌクレオチドとを含む組成物および方法

Publications (4)

Publication Number Publication Date
JP2022525428A JP2022525428A (ja) 2022-05-13
JPWO2020198697A5 JPWO2020198697A5 (https=) 2023-12-15
JP2022525428A5 true JP2022525428A5 (https=) 2023-12-15
JP7631215B2 JP7631215B2 (ja) 2025-02-18

Family

ID=70296147

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557397A Active JP7631215B2 (ja) 2019-03-28 2020-03-27 Ttrガイドrnaと、rnaガイドdna結合剤をコードするポリヌクレオチドとを含む組成物および方法
JP2025016673A Pending JP2025072483A (ja) 2019-03-28 2025-02-04 Ttrガイドrnaと、rnaガイドdna結合剤をコードするポリヌクレオチドとを含む組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025016673A Pending JP2025072483A (ja) 2019-03-28 2025-02-04 Ttrガイドrnaと、rnaガイドdna結合剤をコードするポリヌクレオチドとを含む組成物および方法

Country Status (15)

Country Link
US (2) US20230044994A1 (https=)
EP (1) EP3946598A1 (https=)
JP (2) JP7631215B2 (https=)
KR (1) KR20220004648A (https=)
CN (1) CN113874076A (https=)
AU (1) AU2020244887A1 (https=)
BR (1) BR112021019196A2 (https=)
CA (1) CA3134271A1 (https=)
CO (1) CO2021014559A2 (https=)
EA (1) EA202192636A1 (https=)
IL (1) IL286524A (https=)
MX (1) MX2021011565A (https=)
PH (1) PH12021552301A1 (https=)
SG (1) SG11202110434PA (https=)
WO (1) WO2020198697A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114572A (zh) * 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
JP7543259B2 (ja) 2018-10-18 2024-09-02 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
WO2022246266A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
US20240261435A1 (en) * 2021-06-04 2024-08-08 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting transthyretin (ttr) and uses thereof
KR20240038705A (ko) * 2021-06-22 2024-03-25 인텔리아 테라퓨틱스, 인크. 간 유전자의 생체 내 편집 방법
WO2023185697A2 (en) 2022-03-29 2023-10-05 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of transthyretin amyloidosis
EP4531819A2 (en) 2022-05-25 2025-04-09 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024003805A1 (en) * 2022-06-30 2024-01-04 Geneditbio Limited Methods and compositions for ttr gene editing and therapy using crispr system
EP4590820A2 (en) 2022-09-22 2025-07-30 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease
EP4627083A1 (en) * 2022-11-30 2025-10-08 Arbor Biotechnologies, Inc. Reverse transcriptase-mediated genetic editing of transthyretin (ttr) and uses thereof
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026003582A2 (en) * 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026061971A1 (en) 2024-09-17 2026-03-26 Lonza Ltd Nucleic acid untranslated regions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
KR940703846A (ko) 1991-12-24 1994-12-12 비. 린네 파샬 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
US6169169B1 (en) 1994-05-19 2001-01-02 Dako A/S PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
DK2931898T3 (en) * 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
CA2895155C (en) 2012-12-17 2021-07-06 President And Fellows Of Harvard College Rna-guided human genome engineering
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
EP3265559B1 (en) 2015-03-03 2021-01-06 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
JP6937740B2 (ja) * 2015-07-28 2021-09-22 ダニスコ・ユーエス・インク ゲノム編集システムおよび使用方法
ES2964690T3 (es) 2015-09-21 2024-04-09 Trilink Biotechnologies Llc Método para sintetizar ARN con caperuza 5'
TWI773666B (zh) 2016-03-30 2022-08-11 美商英特利亞醫療公司 Crispr/cas 組分之脂質奈米粒子調配物
WO2018007871A1 (en) * 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
WO2018067447A1 (en) 2016-10-03 2018-04-12 Itellia Therapeutics, Inc. Improved methods for identifying double strand break sites
AR113154A1 (es) * 2017-09-29 2020-01-29 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para edición del genoma
EP3688161A1 (en) * 2017-09-29 2020-08-05 Intellia Therapeutics, Inc. Compositions and methods for ttr gene editing and treating attr amyloidosis
PT3688162T (pt) * 2017-09-29 2024-04-23 Intellia Therapeutics Inc Formulações
WO2019237069A1 (en) * 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Modified guide rnas for gene editing
BR112021005718A2 (pt) * 2018-09-28 2021-06-22 Intellia Therapeutics, Inc. composições e métodos para edição de genes de lactato desidrogenase (ldha)

Similar Documents

Publication Publication Date Title
JP2022525428A5 (https=)
BR102021016837A2 (https=)
CN306226222S (https=)
CN306081297S (https=)
CN305572630S (https=)
CN305537112S (https=)
CN305570484S (https=)
CN305536995S (https=)
CN305536102S (https=)
CN305568930S (https=)
CN305533156S (https=)
CN305531856S (https=)
CN305531118S (https=)
CN305530866S (https=)
CN305530566S (https=)
CN306400452S (https=)
CN306296180S (https=)
CN306293657S (https=)
CN306292821S (https=)
CN306234992S (https=)
CN306234667S (https=)
CN306233292S (https=)
CN306227584S (https=)
CN306227571S (https=)
CN306226615S (https=)